All In Biotech

Drug Trial Radar · NCT01353313

Hydrocortisone for BPD

A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Aug 11, 2011

Primary completion

Sep 21, 2020

Study completion Sep 12, 2024

Sponsor

Lead sponsor
NICHD Neonatal Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Center for Research Resources (NCRR); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); National Center for Advancing Translational Sciences (NCATS)
First posted
May 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 30 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.

Conditions

  • Infant, Newborn
  • Infant, Small for Gestational Age
  • Infant, Very Low Birth Weight
  • Infant, Premature
  • Bronchopulmonary Dysplasia

Interventions

  • HydrocortisoneDrug

    Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows: 4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then 1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days

  • PlaceboDrug

    Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows: 4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then 1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD)Time frame: From day of randomization to 36 weeks post menstrual age
  2. Survival Without Moderate/Severe Neurodevelopmental Impairment (NDI)Time frame: From day of randomization to 22-26 months corrected age

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California - Los Angeles

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • Emory University

    Atlanta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Wayne State University

    Detroit, Michigan

  • Children's Mercy Hospital

    Kansas City, Missouri

  • University of New Mexico

    Albuquerque, New Mexico

  • University of Rochester

    Rochester, New York

  • RTI International

    Durham, North Carolina

  • Duke University

    Durham, North Carolina

  • Cincinnati Children's Medical Center

    Cincinnati, Ohio

  • Case Western Reserve University, Rainbow Babies and Children's Hospital

    Cleveland, Ohio

  • Research Institute at Nationwide Children's Hospital

    Columbus, Ohio

  • Univeristy of Pennsylvania

    Philadelphia, Pennsylvania

  • Brown University, Women & Infants Hospital of Rhode Island

    Providence, Rhode Island

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.